## Neuronetics, Inc. Supplemental Financial and Operating Information

For the period ended September 30, 2022

### Revenue ($ thousands)

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
<td>Q1</td>
</tr>
<tr>
<td>Total U.S. NeuroStar Advanced Therapy System Revenues</td>
<td>$2,594</td>
<td>$2,338</td>
<td>$2,541</td>
<td>$3,620</td>
<td>$1,755</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-23%</td>
<td>-40%</td>
<td>-61%</td>
<td>-31%</td>
<td>-31%</td>
</tr>
<tr>
<td>Total U.S. Treatment Sessions Revenues</td>
<td>$8,193</td>
<td>$6,547</td>
<td>$9,083</td>
<td>$11,029</td>
<td>$9,629</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-7%</td>
<td>-40%</td>
<td>-71%</td>
<td>-2%</td>
<td>18%</td>
</tr>
<tr>
<td>Total U.S. Other Revenues</td>
<td>$390</td>
<td>$382</td>
<td>$404</td>
<td>$397</td>
<td>$419</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-7%</td>
<td>-8%</td>
<td>-5%</td>
<td>6%</td>
<td>7%</td>
</tr>
<tr>
<td>Total U.S. Revenues</td>
<td>$11,177</td>
<td>$9,267</td>
<td>$12,029</td>
<td>$15,046</td>
<td>$11,802</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-11%</td>
<td>-42%</td>
<td>-27%</td>
<td>-12%</td>
<td>6%</td>
</tr>
<tr>
<td>Total International Revenues</td>
<td>$299</td>
<td>$474</td>
<td>$419</td>
<td>$533</td>
<td>$486</td>
</tr>
<tr>
<td>YoY Change</td>
<td>64%</td>
<td>-31%</td>
<td>-47%</td>
<td>64%</td>
<td>63%</td>
</tr>
<tr>
<td>Total Revenues</td>
<td>$11,476</td>
<td>$9,741</td>
<td>$12,448</td>
<td>$15,579</td>
<td>$12,288</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-70%</td>
<td>-47%</td>
<td>-22%</td>
<td>-10%</td>
<td>7%</td>
</tr>
</tbody>
</table>

### U.S. Operating and Financial Metrics

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
<td>Q1</td>
</tr>
<tr>
<td>Total NeuroStar Systems</td>
<td>38</td>
<td>35</td>
<td>39</td>
<td>54</td>
<td>23</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-12%</td>
<td>-43%</td>
<td>-43%</td>
<td>-31%</td>
<td>-39%</td>
</tr>
<tr>
<td>Average Revenue Per Active Site ($) (1)</td>
<td>$9,418</td>
<td>$7,406</td>
<td>$10,218</td>
<td>$12,133</td>
<td>$10,512</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-24%</td>
<td>-50%</td>
<td>-22%</td>
<td>-10%</td>
<td>12%</td>
</tr>
</tbody>
</table>

(1) Average Revenue Per Active Site differs from the average of the quarterly averages due to the cumulative effect of adjustments for those patients whose revenue is not fully recognized until the next quarter.